ALK TKI Sequencing in the Australian Landscape episode artwork

EPISODE · Apr 9, 2026 · 41 MIN

ALK TKI Sequencing in the Australian Landscape

from Conversations in Lung Cancer Research · host Tim Clay, Ben Solomon, Malinda Itchins

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually. (00:00) Welcome and Acknowledgement (00:43) Meet the Expert Guests (01:40) ALK History and Breakthroughs (03:48) Who Gets ALK Lung Cancer (04:57) Workup and Staging Essentials (05:54) Patterns of Spread and Clots (07:24) Second Generation TKIs Standard (09:03) Long Term Toxicities (11:07) Progression Assessment and LAT (12:50) Lorlatinib After Progression (15:46) Lorlatinib First Line Crown Data (17:11) Choosing and Dosing Lorlatinib (20:55) Managing Lorlatinib Side Effects (22:29) Predicting Response and Follow Up (29:30) Next Generation Inhibitors NAL (32:04) Early Stage and Adjuvant TKIs (36:32) Beyond TKIs Chemo and ADCs (39:30) Patient Support and Closing Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube:  https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Episode metadata supplied by the publisher feed · Published Apr 9, 2026

Embed this episode

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

ALK TKI Sequencing in the Australian Landscape

0:00 41:08

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Conversations in Lung Cancer Research?

This episode is 41 minutes long.

When was this Conversations in Lung Cancer Research episode published?

This episode was published on April 9, 2026.

Can I download this Conversations in Lung Cancer Research episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!